Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics


Madrigal Pharmaceuticals, Inc. (MDGL)

Today's Latest Price: $118.19 USD

0.29 (0.25%)

Updated Sep 25 4:00pm

Add MDGL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MDGL Daily Price Range
MDGL 52-Week Price Range

MDGL Stock Price Chart Technical Analysis Charts


MDGL Price/Volume Stats

Current price $118.19 52-week high $127.25
Prev. close $117.90 52-week low $56.82
Day low $117.65 Volume 75,210
Day high $121.50 Avg. volume 171,912
50-day MA $108.31 Dividend yield N/A
200-day MA $96.31 Market Cap 1.82B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.


MDGL Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream


Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data from its Phase 2 NASH study with MGL-3196 (resmetirom) will be presented. Resmetirom is currently in Phase 3 development for the treatment of NASH patients with stage 2-3 fibrosis (ClinicalTrials.gov NCT03900429 and ClinicalTrials.gov/NCT04197479). Rohit Loomba, MD, MHSc, Professor of Medicine (with tenure), Division of Gastroenterology,  Department of Medicine, and Director, NAFLD Research Center and Director, Liver Epidemiology Training Program, University of California at San Diego, will present “Magnetic re...

Yahoo | August 26, 2020

Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Phase 3 MAESTRO clinical trials as rapidly as possible,” said Becky Taub, M.D., CMO and President, Research & Development of Madrigal.  “MAESTRO-NAFLD-1, a 52-week study in which NASH is diagnosed non-invasively, has enrolled well throughout 2020, and we anticipate completion of enrollment as scheduled by the end of 2020.  We expect to report data from an open label 100 mg arm of MAESTRO-NAFLD-1 by the end of this year, including selected data from noninvasive tests: liver fat (MRI-PDFF) at week 16, fibrosis biomarkers, liver enzymes...

Yahoo | August 6, 2020

Should You Avoid Madrigal Pharmaceuticals, Inc. (MDGL)?

In this article you are going to find out whether hedge funds think Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | June 28, 2020

ENDRA Life Sciences' NASH Test Device, TAEUS, At Commercialization Inflection Point

ENDRA Life Sciences Inc. (NDRA) recently announced it is moving forward with the commercialization of its Thermo Acoustic Enhanced UltraSound (TAEUS) device in Europe. The TAEUS device is essentially a point of care ((POC)) or field diagnostic hybrid of an ultrasound and MRI that can monitor the progression of one...

Theodore Zucconi on Seeking Alpha | June 20, 2020

Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals

These two companies are going after the same target, but which one should you bet on today?

The Motley Fool | June 18, 2020

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo 11.68%
3-mo 8.98%
6-mo 68.58%
1-year 38.83%
3-year 220.73%
5-year 96.33%
YTD 29.72%
2019 -19.17%
2018 22.80%
2017 516.04%
2016 21.63%
2015 -86.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.7438 seconds.